



an Open Access Journal by MDPI

Druggability of Proteins in Oncology Targeting Immune Cell Signaling

Guest Editor:

Dr. Victoria Klepsch

Institute of Cell Genetics,
Department for Genetics and
Pharmacology, Peter Mayr Straße
1a, A-6020 Innsbruck, Austria

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editor

Dear Colleagues,

This Special Issue on “Druggability of Proteins in Oncology Targeting Immune Cell Signaling” will mainly focus on known and novel druggable proteins and their potential to induce a potent antitumor immunity for cancer immunotherapy.

Proteins important for an effective antitumor immune response have been extensively studied in the past two decades and have been shown to induce great response rates in some cancer patients. Still, new pathways/proteins, combinatorial approaches, and methods to target druggable proteins are envisioned as a way forward to extend the benefits of clinical immunology therapies to a larger number of cancer patients.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Dr. Victoria Klepsch
Guest Editor



mdpi.com/si/105494

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)